Nasus Pharma’s NS002 Powder Shows Superior Deposition and Freeze-Thaw Stability
Nasus Pharma will present data at AAAAI 2026 showing NS002’s intranasal powder achieves significantly higher nasal deposition than liquid sprays and remains stable across three freeze-thaw cycles. Presentations on March 1 at 9:45 AM will highlight the powder’s rapid epinephrine absorption potential and FMXIN002’s durability under freeze-thaw stress.
1. AAAAI 2026 Presentation Details
Nasus Pharma will present two posters at the AAAAI 2026 Annual Meeting in Philadelphia on March 1 at 9:45 AM detailing NS002’s nasal epinephrine powder performance. Poster IDs 592 and 593 will cover comparisons to liquid sprays and freeze-thaw stability tests in Hall E, Level 2.
2. Superior Nasal Deposition Results
The first poster demonstrates that NS002 powder achieves significantly higher deposition in the nasal cavity compared to liquid epinephrine sprays, potentially enabling faster systemic absorption during anaphylactic emergencies.
3. Freeze-Thaw Stability Findings
The second poster shows that the FMXIN002 intranasal powder maintains formulation integrity and potency after three freeze-thaw cycles, indicating robust stability under storage stress conditions.
4. Development and Future Steps
These findings support NS002 as a needle-free epinephrine delivery candidate, with next steps including further clinical evaluation and regulatory engagements toward potential anaphylaxis treatment approval.